타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | zanidatamab (Ziihera, ZW25, zanidatamab-hrii) Jazz Pharmaceuticals / Zymeworks·HER2 (biparatopic) 35 trials | Immune Checkpoint Inhibitors (Immune Checkpoint Inhibitors) Compugen Ltd·Hepatocellular Carcinoma 90 trials | |
|---|---|---|---|
Overview Program | Imfinzi (durvalumab) | Ziihera (zanidatamab) | Immune Checkpoint Inhibitors |
Overview Company | AstraZeneca | Jazz Pharmaceuticals / Zymeworks | Compugen Ltd |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PD-L1 | HER2 (biparatopic) | Hepatocellular Carcinoma |
Overview Indication | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC | First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract cancer | Biliary Tract Cancer; Immune Checkpoint Inhibitor |
Overview Phase | APPROVED | APPROVED | PHASE_2 |
Overview Status | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m | Dual-epitope binding drives receptor clustering, faster internalization, and stronger signaling blockade than either monoclonal alone. In GEA the label splits IHC 3+ (chemo doublet) from IHC 3+ or 2+/ISH+ (chemo + Tevimbra). | — |
Positioning Known limitation | escape detection by the immune system | HER2 heterogeneity, PI3K pathway activation, and bypass RTK signaling. | — |
Positioning Development positioning | — | 1L GEA with fluoropyrimidine-platinum ± Tevimbra; 2L+ BTC monotherapy | — |
MoA Mechanism | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. | Simultaneous binding of two non-overlapping HER2 epitopes crosslinks adjacent receptors, causing receptor clustering, internalization, and degradation alongside ADCC and complement activity. | target of rapamycin (mTOR) pathway |
MoA Biomarker | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. | GEA: PATHWAY 4B5 IHC and VENTANA Dual ISH. IHC 3+ for chemo doublet; IHC 3+ or IHC 2+/ISH+ when Tevimbra is added. BTC: HER2 IHC 3+. | biomarkers |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse | — | — |
Toxicology Major finding | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. | — |
Toxicology CRS | N/A | N/A | — |
Clinical Safety signal | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_2 |
Clinical Trial activity | No active/completed counts | No active/completed counts | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | zanidatamab (Ziihera, ZW25, zanidatamab-hrii) Jazz Pharmaceuticals / Zymeworks·HER2 (biparatopic) 35 trials | Immune Checkpoint Inhibitors (Immune Checkpoint Inhibitors) Compugen Ltd·Hepatocellular Carcinoma 90 trials | |
|---|---|---|---|
Overview Program | Imfinzi (durvalumab) | Ziihera (zanidatamab) | Immune Checkpoint Inhibitors |
Overview Company | AstraZeneca | Jazz Pharmaceuticals / Zymeworks | Compugen Ltd |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PD-L1 | HER2 (biparatopic) | Hepatocellular Carcinoma |
Overview Indication | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC | First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract cancer | Biliary Tract Cancer; Immune Checkpoint Inhibitor |
Overview Phase | APPROVED | APPROVED | PHASE_2 |
Overview Status | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m | Dual-epitope binding drives receptor clustering, faster internalization, and stronger signaling blockade than either monoclonal alone. In GEA the label splits IHC 3+ (chemo doublet) from IHC 3+ or 2+/ISH+ (chemo + Tevimbra). | — |
Positioning Known limitation | escape detection by the immune system | HER2 heterogeneity, PI3K pathway activation, and bypass RTK signaling. | — |
Positioning Development positioning | — | 1L GEA with fluoropyrimidine-platinum ± Tevimbra; 2L+ BTC monotherapy | — |
MoA Mechanism | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. | Simultaneous binding of two non-overlapping HER2 epitopes crosslinks adjacent receptors, causing receptor clustering, internalization, and degradation alongside ADCC and complement activity. | target of rapamycin (mTOR) pathway |
MoA Biomarker | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. | GEA: PATHWAY 4B5 IHC and VENTANA Dual ISH. IHC 3+ for chemo doublet; IHC 3+ or IHC 2+/ISH+ when Tevimbra is added. BTC: HER2 IHC 3+. | biomarkers |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse | — | — |
Toxicology Major finding | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. | — |
Toxicology CRS | N/A | N/A | — |
Clinical Safety signal | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Embryo-fetal toxicity warning. Diarrhea, infusion-related reactions, and left ventricular dysfunction require monitoring, as with the HER2 antibody class. | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_2 |
Clinical Trial activity | No active/completed counts | No active/completed counts | — |
추천 비교
추천 비교